SEC Form 4 · accession 0000899243-17-016988
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles J Homcy
Director
Period of report
Jun 1, 2017
Accepted (ET)
Jun 22, 2017 · 9:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2017 | S | 18,299 | $26.5777 | D | 219,429 | D | |
| Common StockF2 | Jun 2, 2017 | S | 49,959 | $26.9205 | D | 169,470 | D | |
| Common StockF3 | Jun 2, 2017 | S | 31,742 | $27.6354 | D | 137,728 | D | |
| Common Stock | holding | — | — | — | 1,600 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $26.50 to $26.80. The price reported above reflects the weighted average price. The Reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices ranging from $26.38 to $27.35. The price reported above reflects the weighted average price. The Reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $27.38 to $27.90. The price reported above reflects the weighted average price. The Reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.